Business Report

The report covers Zeria's fiscal year 2024, highlighting consolidated net sales of ¥87,311 million and operating profit of ¥12,197 million, both record highs for a third consecutive fiscal year. It attributes growth to overseas Ethical Pharmaceuticals sales, especially Dificlir in Europe, and strong Consumer Healthcare performance led by Hepalyse. The company also launched Veltassa in Japan in March 2025 and Hepalyse W Shine in October 2024.

Report type

Annual Report

Class

Financial

Scope

Full report

Fiscal year

2024

Period

1 April 2024 – 31 March 2025

Language

English

Pages

 

File size